GlassScriptPhysician profile
Wayne C Paulekas
NPI 1730166422
$3,895.58
in general payments reported to CMS, 2019-2025
43 companies · $967 in 2025
The $967 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,141 · 2020: $424 · 2021: $456 · 2022: $418 · 2023: $192 · 2024: $298 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $472.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $458.24 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $443.98 | 2021-2025 | |
| Glaxosmithkline, LLC. | $275.93 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $273.03 | 2019-2024 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $238.84 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.28 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $151.47 | 2019-2025 | |
| Allergan, INC. | $140.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.15 | 2019-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $80.01 | 2025 | Voquezna |
| Novartis Pharmaceuticals Corporation | $74.72 | 2019-2025 | |
| Exact Sciences Corporation | $63.64 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $57.36 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $56.41 | 2019-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Paulekas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.